Hepatitis B Core Antigen Expression in Hepatocytes Reflects Viral Response to Entecavir in Chronic Hepatitis B Patients
1
조회
0
다운로드
1
인용
0
참고문헌
초록
Background/Aims: Hepatitis B core antigen is known to be a major target for virus-specific T cells and also reflects the progression of liver dissease and viral replication. Hepatitis B core antigen expression in hepatocytes leads to altered histological activity, viral replication, and immune response. The purpose of this study is to evaluate whether the topographical distribution of hepatitis B core antigen expression can predict the viral response to entecavir in patients with chronic hepatitis B. Methods: We enrolled 91 patients with treatment-naïve chronic hepatitis B. All the patients underwent liver biopsy, and the existence and pattern of hepatitis B core antigen evaluated by immunohistochemistry. All patients received 0.5 mg of entecavir daily following a liver biopsy. We checked the viral response at 3, 6, and 12months during antiviral therapy. Results: Of the 91 patients,64 (70.3%) had hepatitis B core antigen expression. Of the subcellular patterns, the mixed type was dominant (n=48,75%). The viral response was significantly higher in the hepatitis B core antigen-negative group than in the hepatitis B core antigen-positive group (88.9% and 54.7%, respectively;p=0.001) after 12 months of entecavir therapy. Conclusions:Chronic hepatitis B patients who are hepatitis B core antigen-negative have a better response to entecavir therapy than do hepatitis B core antigen-positive patients.
Abstract
Background/Aims: Hepatitis B core antigen is known to be a major target for virus-specific T cells and also reflects the progression of liver dissease and viral replication. Hepatitis B core antigen expression in hepatocytes leads to altered histological activity, viral replication, and immune response. The purpose of this study is to evaluate whether the topographical distribution of hepatitis B core antigen expression can predict the viral response to entecavir in patients with chronic hepatitis B. Methods: We enrolled 91 patients with treatment-naïve chronic hepatitis B. All the patients underwent liver biopsy, and the existence and pattern of hepatitis B core antigen evaluated by immunohistochemistry. All patients received 0.5 mg of entecavir daily following a liver biopsy. We checked the viral response at 3, 6, and 12months during antiviral therapy. Results: Of the 91 patients,64 (70.3%) had hepatitis B core antigen expression. Of the subcellular patterns, the mixed type was dominant (n=48,75%). The viral response was significantly higher in the hepatitis B core antigen-negative group than in the hepatitis B core antigen-positive group (88.9% and 54.7%, respectively;p=0.001) after 12 months of entecavir therapy. Conclusions:Chronic hepatitis B patients who are hepatitis B core antigen-negative have a better response to entecavir therapy than do hepatitis B core antigen-positive patients.
참고문헌 (19)
- Kim CW, "Correlation of hepatitis B core antigen and beta-catenin expression on hepatocytes in chronic hepatitis B virus infection: relevance to the severity of liver damage and viral replication", J Gastroenterol Hepatol, 22, pp.1534~1542 (2007)
- Hsu HC, "Biologic and prognostic significance of hepatocyte hepatitis B core antigen expressions in the natural course of chronic hepatitis B virus infection", J Hepatol, 5, pp.45~50 (1987)
- Chu CM, "Intrahepatic distribution of hepatitis B surface and core antigens in chronic hepatitis B virus infection. Hepatocyte with cytoplasmic", membranous hepatitis B core antigen as a possible target for immune hepatocytolysis, 1987, pp.92, 220~225
- Naoumov NV, "Detection of hepatitis B virus antigens in liver tissue. A relation to viral replication and histology in chronic hepatitis B infection", Gastroenterology, 99, pp.1248~1253 (1990)
- Hadziyannis SJ, "Analysis of liver disease, nuclear HBcAg, viral replication, and hepatitis B virus DNA in liver and serum of HBeAg vs. anti-HBe positive carriers of hepatitis B virus", Hepatology, 3, pp.656~662 (1983)
- Serinoz E, "Nuclear localization of hepatitis B core antigen and its relations to liver injury, hepatocyte proliferation, and viral load", J Clin Gastroenterol, 36, pp.269~272 (2003)
- Uzun Y, "Hepatitis B core antigen expression pattern reflects the response to anti-viral treatment", J Gastroenterol Hepatol, 21, pp.977~981 (2006)
- Lok AS, "Chronic hepatitis B: update 2009", Hepatology, 50, pp.661~662 (2009)
- Hubscher SG, "Histological grading and staging in chronic hepatitis: clinical applications and problems", J Hepatol, 29, pp.1015~1022 (1998)
- Yu E, "Korean Study Group for the Pathology of Digestive Diseases. Histologic grading and staging of chronic hepatitis: on the basis of standardized guideline proposed by the Korean Study Group for the Pathology of Digestive Diseases", Korean J Hepatol, 9, pp.42~46 (2003)
- Wieland S, "Genomic analysis of the host response to hepatitis B virus infection", Proc Natl Acad Sci U S A, 101, pp.6669~6674 (2004)
- Ferrari C, "Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen", J Clin Invest, 88, pp.214~222 (1991)
- Thimme R, "CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection", J Virol, 77, pp.68~76 (2003)
- Myung Su Son, "Associations of Expressions of HBcAg and HBsAg with the Histologic Activity of Liver Disease and Viral Replication", Gut and Liver, 2(3), pp.166~173 (2008), 거트앤리버 발행위원회
- Chu CM, "Subcellular localization of hepatitis B core antigen in relation to hepatocyte regeneration in chronic hepatitis B", Gastroenterology, 109, pp.1926~1932 (1995)
- Chu CM, "The degrees of hepatocyte nuclear but not cytoplasmic expression of hepatitis B core antigen reflect the level of viral replication in chronic hepatitis B virus infection", J Clin Microbiol, 35, pp.102~105 (1997)
- 시계동, "만성 B형간염 환자에서 hepatitis B core antigen 의 발현과 분포 위치에 따른 라마부딘의 치료반응", Clinical and Molecular Hepatology, 14(2), pp.197~205 (2008), 대한간학회
- You J, "Impact of viral replication inhibition by entecavir on peripheral T lymphocyte subpopulations in chronic hepatitis B patients", BMC Infect Dis, 8, pp.123~ (2008)
- Chisari FV, "Hepatitis B virus immunopathogenesis", Annu Rev Immunol, 13, pp.29~60 (1995)